Arrowhead Pharmaceuticals Reports Positive Phase 3 Plozasiran Results
PASADENA, Calif., July 22, 2026 Arrowhead Pharmaceuticals announced positive topline results from its pivotal Phase 3 SHASTA-3 and SHASTA-4...
RNAi Therapy
Advertisement
AviadoBio Advances AVB-406 Gene Therapy for Alzheimer’s
LONDON, May 14, 2026 AviadoBio presented new preclinical data at the American Society of Gene and Cell Therapy (ASGCT)...
Arrowhead Pharmaceuticals and Madrigal Announce MASH Deal
PASADENA, Calif., United States – May 5, 2026 Arrowhead Pharmaceuticals Inc. has entered into an exclusive global licensing agreement...
Arrowhead Pharma and Novartis Advance RNAi Therapy for Parkinson’s
Pasadena, CA – October 21, 2025 – Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has officially completed its global licensing and...
Silexion’s SIL204 Shows Preclinical Promise in Pancreatic Cancer
GRAND CAYMAN, Cayman Islands, Sept. 11, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company developing RNA...
Advertisement
